ArticlebioRxiv : the preprint server for biology2025
NeSyDPP4-QSAR: A Neuro-Symbolic AI Approach for Potent DPP-4-Inhibitor Discovery in Diabetes Treatment.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes Mellitus (DM) is a global epidemic and among the top ten leading causes of mortality (WHO, 2019), projected to rank seventh by 2030. The US National Diabetes Statistics Report (2021) states that 38.4 million Americans have diabetes. Dipeptidyl Peptidase-4 (DPP-4) is an FDA-approved target for type 2 diabetes mellitus (T2DM) treatment. However, current DPP-4 inhibitors are associated with adverse effects, including gastrointestinal issues, severe joint pain (FDA safety warning), nasopharyngitis, hypersensitivity, and nausea. Identifying novel inhibitors is crucial. Direct in vivo DPP-4 inhibition assessment is costly and impractical, making in silico IC50 prediction a viable alternative. Quantitative Structure-Activity Relationship (QSAR) modeling is a widely used computational approach for chemical substance assessment. We employ LTN, a neuro-symbolic approach, alongside DNN and transformers as baselines. DPP-4-related data is sourced from PubChem, ChEMBL, BindingDB, and GTP, comprising 6,563 bioactivity records (SMILES-based compounds with IC50 values) after deduplication and thresholding. A diverse set of features including descriptors (CDK Extended-PaDEL), fingerprints (Morgan), chemical language model embeddings (ChemBERTa2), LLaMa 3.2, and physicochemical properties is used to train the NeSyDPP4-QSAR model. The NeSyDPP4-QSAR model yielded the highest accuracy, incorporating CDKextended and Morgan fingerprints, with an accuracy of 0.9725, an F1-score of 0.9723, an ROC AUC of 0.9719, and an MCC of 0.9446. The performance was benchmarked against two standard baseline models: a deep neural network and a transformer. To ensure fair comparisons, DNN models used the equivalent attributes with the same dimension and network configuration as NeSyDPP4-QSAR. Our findings showed that integrating the Neuro-symbolic strategy (neural network-based learning and symbolic reasoning) holds immense potential for discovering drugs that can inhibit diabetes mellitus and classifying biological activities that inhibit it.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.